The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First Dosing In TP-05 Lyme Trial
Tarsus Pharmaceuticals has initiated a Phase 2 trial for TP-05, an oral prophylactic for Lyme disease, marking the company's expansion beyond eye care into infectious disease prevention. This development could transform its investment narrative by diversifying its product pipeline beyond its existing commercial asset, XDEMVY, while also leveraging its lotilaner platform. The company's financial projections indicate significant revenue and earnings growth by 2028, with some analysts forecasting even higher figures.
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS
Capricorn Fund Managers Ltd significantly reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 90.8% in the fourth quarter, selling 218,038 shares. This divestment leaves them with 21,982 shares valued at approximately $1.8 million. Several company insiders have also been net sellers, with the CEO and General Counsel selling shares totaling over $1 million, while analysts maintain a "Moderate Buy" consensus rating with an average target price of $91.83.
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins
Tarsus Pharmaceuticals has initiated a Phase 2 trial for TP-05, an oral candidate for Lyme disease, drawing attention to its valuation. Despite recent progress and a strong multi-year stock performance, its share price has cooled from highs, leading to questions about whether it's an opportunity or if future growth is already priced in. While one narrative suggests it's 19.7% undervalued with a fair value of $87.50, another view based on its P/S ratio of 6.6x suggests a more cautious outlook compared to the industry average.
JPMorgan Chase & Co. Sells 63,420 Shares of Tarsus Pharmaceuticals, Inc. $TARS
JPMorgan Chase & Co. reduced its stake in Tarsus Pharmaceuticals, Inc. by 45.1%, selling 63,420 shares and now holding 77,190 shares valued at approximately $4.59 million. The article also notes significant insider selling, with a director and CEO collectively disposing of nearly 24,500 shares, and analysts maintaining a "Moderate Buy" rating with an average target price of $91.83 for TARS.
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins
Tarsus Pharmaceuticals (TARS) has initiated a Phase 2 trial for TP-05, an oral candidate for Lyme disease prevention, bringing fresh attention to the company. While the stock has seen a 4.9% return in the last 7 days, its 90-day return shows a 14.2% decline, though it boasts significant long-term returns. The article discusses whether Tarsus, with growing revenue and a loss-making income, is undervalued or if its future growth is already priced into its current share price of US$70.22.
Price-Driven Insight from (TARS) for Rule-Based Strategy
This article provides a price-driven analysis for Tarsus Pharmaceuticals Inc. (NASDAQ: TARS), highlighting a positive near-term sentiment within a long-term strength context despite mid-term weakness. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, complete with entry, target, and stop-loss zones. The analysis also features multi-timeframe signal analysis and AI-generated signals for support and resistance levels.
TARS Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Tarsus Pharmaceuticals Inc (TARS) as of April 2, 2026. It indicates an overall "Buy" consensus based on various technical indicators, including moving averages and oscillators. The analysis details support and resistance levels, RSI, MACD signals, and performance relative to moving averages, showing the stock is trading above its long-term moving averages.
Biopharmaceutical company Tarsus Pharmaceuticals, Inc. announced that its innovative oral tablet TP-05 (lotilaner) for the potential prevention of Lyme disease has dosed the first subject in the Phase 2 clinical trial "Calliope".
Tarsus Pharmaceuticals, Inc. has initiated a Phase 2 clinical trial named "Calliope" for its oral tablet TP-05 (lotilaner), aimed at the potential prevention of Lyme disease. The first subject in the trial has been dosed, marking a significant step in evaluating the drug's application in disease prevention. This study will assess the efficacy and safety of lotilaner for this purpose.
Tarsus Pharmaceuticals, Inc. recently disclosed the latest progress on its leading vaccine candidate under development for Lyme disease.
Tarsus Pharmaceuticals, Inc. has provided an update on its Lyme disease vaccine candidate, announcing that patient recruitment is expected to conclude during the tick-active season in 2026. The company anticipates releasing key topline results of the clinical trial in the first half of 2027. Positive data could lead to regulatory applications and address a significant unmet medical need in Lyme disease prevention.
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 clinical trial (Calliope) for TP-05 (lotilaner), an oral tablet designed to prevent Lyme disease by killing infected ticks. The study aims to enroll 700 healthy adults in U.S. endemic regions, with topline results expected in the first half of 2027. This investigational prophylactic approach addresses the urgent public health challenge of Lyme disease, for which no FDA-approved pharmacological prevention currently exists.
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Tarsus Pharmaceuticals has dosed its first participant in the Phase 2 Calliope clinical trial for TP-05 (lotilaner), an investigational oral therapy aimed at preventing Lyme disease by killing infected ticks. This randomized, double-blind, placebo-controlled study will involve approximately 700 healthy adults in U.S. endemic regions, with topline results expected in the first half of 2027. The company hopes to shift the paradigm from treating Lyme disease after infection to proactive prevention, as there are currently no FDA-approved pharmacological prophylactic options for the condition.
Tarsus Pharmaceuticals, Inc. recently disclosed the latest progress on its leading vaccine candidate under development for Lyme disease.
Tarsus Pharmaceuticals, Inc. has provided an update on its Lyme disease vaccine candidate, with patient recruitment expected to conclude during the tick-active season in 2026. The company anticipates releasing key topline results in the first half of 2027. Positive data could lead to regulatory applications and address a significant unmet medical need in Lyme disease prevention.
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
Barclays analyst Jenna Davidner has reiterated a Buy rating for Tarsus Pharmaceuticals (TARS.US), maintaining a target price of $100. According to TipRanks data, Davidner has a 0.0% success rate and an average return of -16.3% over the past year. This information is intended for informational purposes only and does not constitute investment advice.
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors
Tarsus Pharmaceuticals received a significant boost with its partner Grand Pharmaceutical Group securing approval in China for TP-03 (XDEMVY) to treat Demodex blepharitis, which triggered a US$15 million milestone payment. This approval validates TP-03's global clinical profile and opens a new revenue stream through royalties and future regulatory achievements in Greater China. The event strengthens Tarsus's balance sheet and global growth prospects, though the company still faces near-term dependence on U.S. XDEMVY execution and risks associated with high commercial spend against a single primary revenue driver.
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors
Tarsus Pharmaceuticals received National Medical Products Administration approval in China for its drug TP-03 (XDEMVY) to treat Demodex blepharitis, triggering a US$15 million milestone payment from its partner Grand Pharmaceutical Group. This approval validates TP-03's global profile and opens new revenue streams through royalties, strengthening Tarsus's financial flexibility. While the approval expands the market opportunity, investors should still consider the company's near-term dependence on U.S. XDEMVY execution and commercial spend.
Vanguard Realignment: Tarsus (NASDAQ: TARS) Ownership Reported as 0% by Parent
The Vanguard Group has filed an Amendment No. 2 to a Schedule 13G/A, reporting 0 shares beneficially owned of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) common stock, representing 0% of its class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately in accordance with SEC Release No. 34-39538. This means while The Vanguard Group itself no longer reports ownership, its affiliates may still hold and will separately disclose shares of Tarsus.
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS)
This article summarizes recent analyst ratings for three healthcare companies: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR), and Tarsus Pharmaceuticals (TARS). Cibus received a Hold rating from Jefferies with a $3.00 price target, while Arrowhead Pharmaceuticals was given a Buy rating by H.C. Wainwright with a $100.00 price target. Tarsus Pharmaceuticals also received a Buy rating from Mizuho Securities, with a $101.00 price target, reflecting a generally positive outlook on these stocks in the healthcare sector.
Q2 EPS Estimate for Tarsus Pharmaceuticals Lifted by Analyst
Lifesci Capital has increased its Q2 2026 EPS estimate for Tarsus Pharmaceuticals (NASDAQ:TARS) from ($0.36) to ($0.01) and maintained a "Strong-Buy" rating. While analyst ratings are mixed, the consensus is a "Moderate Buy" with a target price of $91.83. Insider selling of 79,391 shares totaling $5.43 million has occurred in the past 90 days.
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade
Tarsus Pharmaceuticals' COO, Seshadri Neervannan, sold 2,989 shares of common stock for $66.75 per share on March 20, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following this transaction, Neervannan directly holds 82,791 shares, with an additional 475 shares indirectly held by his daughter, for which he disclaims beneficial ownership. The Form 4 filing details this change in beneficial ownership and confirms the absence of any option exercises.
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals announced that its TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., has been approved in China for Demodex blepharitis, leading to a $15 million milestone payment to Tarsus. This approval, secured by Tarsus' partner Grand Pharmaceutical Group Limited, marks TP-03 as the first and only approved therapy for the condition in the Greater China region. Tarsus is also eligible for further regulatory milestones, sales thresholds, and tiered royalties from Grand Pharma.
Tarsus Pharmaceuticals shares rise on China drug approval milestone
Tarsus Pharmaceuticals' shares increased by 3.5% after its partner, Grand Pharmaceutical Group, received approval in China for the eye drug TP-03, known as Xdemvy in the U.S. This approval for Demodex blepharitis triggers a $15 million milestone payment for Tarsus, with potential for further regulatory, sales, and royalty payments as the drug is the first approved treatment for the condition in China. Grand Pharmaceutical Group holds exclusive rights for the drug in Greater China, where over 40 million people are affected by Demodex blepharitis.
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals, Inc. announced that its partner, Grand Pharmaceutical Group Limited, has received regulatory approval in China for TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY in the U.S., for the treatment of Demodex blepharitis. This approval triggered a $15 million milestone payment to Tarsus and marks the first and only approved therapy to address the root cause of the condition in Greater China. Tarsus is also eligible for additional regulatory milestones, sales threshold payments, and tiered royalties from Grand Pharma.
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals announced that its partner, Grand Pharmaceutical Group Limited, has received regulatory approval for TP-03 (lotilaner ophthalmic solution) 0.25% in China for Demodex blepharitis, leading to a $15 million milestone payment to Tarsus. This approval marks the first and only therapy in the region to address the root cause of the condition, affecting over 40 million people. Tarsus is also eligible for additional regulatory, sales, and tiered royalty payments from Grand Pharma.
China clears first Demodex blepharitis treatment for 40 million people
Tarsus Pharmaceuticals announced that its partner, Grand Pharmaceutical Group, has received NMPA approval in China for TP-03 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. This approval triggers a $15 million milestone payment to Tarsus and makes TP-03 the first and only approved therapy for this condition in the Greater China region, which affects over 40 million people. Tarsus is also eligible for additional regulatory milestones, sales-based payments, and tiered royalties from Grand Pharma.
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals announced that its partner Grand Pharmaceutical Group Limited has received regulatory approval in China for TP-03 (lotilaner ophthalmic solution) 0.25%, branded as XDEMVY in the U.S., for the treatment of Demodex blepharitis. This approval triggers a $15 million milestone payment to Tarsus, with potential for further payments based on additional regulatory milestones, sales thresholds, and tiered royalties in the Greater China region. The approval marks TP-03 as the first and only therapy approved for this condition in the region, addressing a significant unmet medical need.
LifeSci Capital Remains a Buy on Tarsus Pharmaceuticals (TARS)
LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a price target of $95.00. This is despite negative corporate insider sentiment, with more insiders selling shares recently. The company reported a significant increase in quarterly revenue to $151.67 million, though it still had a GAAP net loss of $8.37 million.
[144] Tarsus Pharmaceuticals, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Tarsus Pharmaceuticals, Inc. (TARS) made on March 17, 2026. The filing indicates a proposed sale of 2,111 shares of common stock with an aggregate market value of $146,534.43, acquired through restricted stock vesting. The report details the filer and issuer information, the nature of the acquisition, and other relevant securities data required by Rule 144.
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)
This article analyzes Tarsus Pharmaceuticals (TARS) stock, which has recently experienced a 16.4% dip. It suggests that this downturn might present a buying opportunity for investors. The article likely delves into specific reasons supporting a "buy the dip" strategy for TARS, potentially discussing company fundamentals, recent news, or market analysis.
Seshadri Neervannan to sell TARS shares (NASDAQ: TARS) — March dispositions listed
Seshadri Neervannan has reported proposed and completed sales of Common Stock of Tarsus Pharmaceuticals (NASDAQ: TARS) in a recent Form 144 filing. The filing details open-market sales totaling 19,690 shares across four dates in March 2026, with aggregate proceeds listed for each transaction. Additionally, the filing indicates the vesting of 2,989 restricted shares on three separate dates in March 2026, classified as compensation.
Azamian, Tarsus Pharmaceuticals CEO, sells $2.36m in stock
Bobak R. Azamian, CEO of Tarsus Pharmaceuticals (NASDAQ:TARS), recently sold 34,603 shares worth approximately $2.36 million to cover tax withholding obligations. Following these transactions, Azamian directly owns 33,421 shares and indirectly 857,991 shares. The company recently reported strong financial results for Q4 2025, with net product sales of $151.7 million, driven by its product XDEMVY.
Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades
Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold 12,274 shares of common stock in tax-related transactions between March 17 and March 19, 2026, at prices ranging from $67 to $69.42 per share. These sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to restricted stock unit vesting, not discretionary trades. Following these sales, Whitfield directly holds 35,028 shares of Tarsus Pharmaceuticals common stock.
Tarsus Pharma general counsel Wahl sells $850k in stock
Tarsus Pharmaceuticals General Counsel Bryan Wahl sold 12,440 shares of company stock between March 17-19, 2026, totaling approximately $850,417. These “sell to cover” transactions were mandated to meet tax withholding obligations from vested Restricted Stock Units and were not discretionary. Despite these sales, Tarsus Pharmaceuticals shows strong financial health, with recent robust Q4 2025 results driven by its flagship product, XDEMVY.
TARS SEC Filings - Tarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Tarsus Pharmaceuticals Inc.'s (NASDAQ: TARS) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents, with AI-powered summaries. Recent filings include insider stock option and RSU grants to executives and a director, as well as an insider sale. The article also highlights the company's strong 2025 performance for XDEMVY sales, increased revenue, and reduced net loss, alongside ongoing pipeline development.
Tarsus Pharmaceuticals Insider Sold Shares Worth $772,444, According to a Recent SEC Filing
An insider at Tarsus Pharmaceuticals (NASDAQ:TARS) sold shares worth $772,444, as reported in a recent SEC filing. This transaction is part of several insider sales reported by the company, highlighting ongoing activity by its executives and other insiders. Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on eye care, with its lead product XDEMVY targeting Demodex blepharitis.
TARS SEC Filings - Tarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Tarsus Pharmaceuticals (TARS) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider trading forms. It highlights the company's focus on eye care therapeutics, led by XDEMVY, and offers AI-powered tools to summarize and interpret these regulatory documents. Recent filings detail board appointments, insider transactions, corporate presentations, and stock sales by executives.
TARS SEC Filings - Tarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Tarsus Pharmaceuticals (TARS) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Stock Titan offers AI-powered tools to summarize these documents, highlight key sections, and explain technical language. The article also lists recent filings, such as a Form 144 for a proposed sale of 6,000 shares and a 10-Q quarterly earnings report.
Tax-driven stock sale by Tarsus (TARS) chief commercial officer
Tarsus Pharmaceuticals' Chief Commercial Officer, Aziz Mottiwala, sold 13,056 shares of common stock between March 17-19, 2026. These sales, totaling approximately $67-69 per share, were mandated by the company as "sell to cover" transactions to satisfy tax obligations on vested Restricted Stock Units, not discretionary investment decisions. After these transactions, Mottiwala directly holds 61,480 shares of Tarsus Pharmaceuticals.
Tarsus (TARS) officer sells 6,430 shares in mandated tax sell-to-cover
Jeffrey S. Farrow, an officer at Tarsus Pharmaceuticals, Inc. (TARS), sold 6,430 shares of common stock at prices between $67.00 and $69.42. These transactions were mandated "sell to cover" sales to fund tax withholding obligations from vesting restricted stock units and do not reflect discretionary trading. Following the sales, Farrow directly holds 43,316 Tarsus shares, maintaining a substantial equity stake in the company.
Tarsus (NASDAQ: TARS) counsel sells shares to cover RSU tax
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) General Counsel, Bryan Wahl, sold 12,440 shares of common stock across three days for prices ranging from $67.00 to $69.42 per share. These sales were not discretionary but were mandated by the company's "sell-to-cover" policy to satisfy tax withholding obligations arising from the vesting of restricted stock units. After these transactions, Wahl directly holds 63,959 shares of Tarsus's common stock.
Tarsus (NASDAQ: TARS) CMO sells shares to cover RSU tax withholding
Tarsus Pharmaceuticals' Chief Medical Officer, Elizabeth Yeu, sold 1,144 shares of common stock between March 17-19, 2026, to cover tax withholding obligations related to vested Restricted Stock Units (RSUs). These "sell-to-cover" transactions were mandated by the company and not discretionary. Following the sales, Yeu directly holds 23,308 common shares and has additional indirect holdings through a Roth IRA and a 401(k) plan.
Tarsus Pharma COO Neervannan Seshadri sells $772k in shares
Tarsus Pharmaceuticals, Inc. COO Neervannan Seshadri sold 11,324 shares of common stock for a total of $772,443 between March 17 and March 19, 2026. These sales were primarily to cover tax withholding obligations related to Restricted Stock Units. The company also reported strong financial results for Q4 2025 with $151.7 million in net product sales.
Tarsus Pharma COO Neervannan Seshadri sells $772k in shares By Investing.com
Neervannan Seshadri, COO of Tarsus Pharmaceuticals, Inc., sold 11,324 shares of company stock between March 17 and March 19, 2026, totaling $772,443. These sales were primarily to cover tax withholding obligations related to vested Restricted Stock Units. Despite these sales, Tarsus Pharmaceuticals recently reported strong financial results for Q4 2025, with significant revenue growth driven by its product XDEMVY.
Farrow Jeffrey S of Tarsus Pharma sells $439k in shares
Jeffrey S. Farrow, CFO and CSO of Tarsus Pharmaceuticals (NASDAQ: TARS), sold 6,430 shares worth $439,566 between March 17 and March 19, 2026. These transactions, executed to cover tax withholding obligations, leave him with 43,316 directly owned shares. Tarsus Pharmaceuticals maintains a strong balance sheet and recently reported robust Q4 2025 financial results with $151.7 million in net product sales.
Tarsus Pharmaceuticals Insiders Sold Shares Worth Over $5.1M
Several key insiders at Tarsus Pharmaceuticals, including the Chief Commercial Officer, COO, President/CEO, Chief Human Resources Officer, and General Counsel, sold shares totaling over $5.1 million. The sales were conducted at weighted average prices ranging from $68.19 to $68.37 per share, with individual transaction prices between $67.00 and $69.42. The article lists each officer's title, the amount of their sale, and their remaining direct and indirect share ownership.
Tarsus Pharmaceuticals (TARS) COO mandated sell-to-cover totals 11,324 shares
Tarsus Pharmaceuticals' COO, Seshadri Neervannan, sold 11,324 shares of common stock between March 17-19, 2026, for tax withholding related to restricted stock vesting. These transactions were mandated "sell to cover" sales, not discretionary trades, occurring at prices between $67.00 and $69.42 per share. Following these sales, Neervannan directly holds 85,780 shares, and disclaims beneficial ownership of an additional 475 shares held by his daughter.
Tarsus Pharmaceuticals (TARS) CEO sells 34,603 shares to cover taxes
Tarsus Pharmaceuticals CEO Bobak R. Azamian sold 34,603 shares of common stock in open-market transactions. These sales, executed at prices between $67.00 and $69.42 per share, were solely to cover tax withholding obligations tied to restricted stock unit vesting ("sell to cover" arrangement), not discretionary trading. Following these transactions, Azamian directly holds 33,421 common shares and indirectly controls 857,991 shares through the Bobak Azamian Living Trust.
TARS (NASDAQ: TARS) insider filings show proposed sale and recent dispositions
A recent Form 144 filing for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) indicates a proposed sale of 11,964 vested restricted common shares. The filing also detailed recent dispositions by insider Bobak Azamian, who sold 10,972 shares on March 17, 2026, and 11,667 shares on March 18, 2026, with associated dollar amounts of $761,618.09 and $801,637.24, respectively. The proposed sale of vested shares was acquired through restricted stock vesting and is to be handled by Fidelity Brokerage Services LLC.
TARS (NASDAQ: TARS) insider files Form 144 to resell 4,589 shares after vesting
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has filed a Form 144 indicating a proposed sale of 4,589 shares of common stock by an insider following a restricted stock vesting event on March 18, 2026. The filing also detailed three previous sales in March totaling 8,366, 3,125, and 3,610 shares, with reported proceeds. Analysts view these transactions as routine insider dispositions and vesting-related resale activity, with a neutral impact on the market.
TARS (NASDAQ: TARS) insider sale notice; Bryan Wahl disposed of 8,209 shares
Tarsus Pharmaceuticals (NASDAQ: TARS) filed a Form 144, indicating a proposed sale of 4,231 shares of common stock. The filing also detailed recent dispositions by Bryan Wahl, totaling 8,209 shares across two sales on March 17 and March 18, 2026. These transactions, including a restricted stock vesting classified as compensation, are considered routine disclosures related to insider activity.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Analysts
Tarsus Pharmaceuticals (NASDAQ:TARS) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $91.83. Despite mixed Q4 2025 financial results, including an EPS miss and revenue beat, the company remains unprofitable. Insider activity shows recent share sales by a director and CEO, while institutional investors hold a significant majority of the stock.
